New drug JR8603 enters first human trial for Hard-to-Treat cancers

NCT ID NCT06783569

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This early-stage trial tests the safety and effectiveness of a new drug called JR8603 in people with advanced solid tumors, including stomach and colorectal cancers, who have not responded to standard treatments. Participants receive JR8603 by IV infusion three times per month. The study will look for side effects and measure whether tumors shrink.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
JR8603 (a drug given by IV infusion)
What this could lead to
If successful, this could lead to a new treatment option for people with advanced solid tumors who have not responded to standard therapies.
What could go wrong
This is a very early Phase 1 trial with only 94 participants, so it is not yet known if JR8603 is safe or effective. There may be side effects, and the drug may not shrink tumors.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Harbin Medical University Cancer Hospital

    RECRUITING

    Harbin, Heiljiang Province, 150040, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • Liaoning Cancer Hospital

    RECRUITING

    Shenyang, Liaoning, 110042, China

    Contact

More trials for these conditions

Other studies related to the condition(s) this trial covers.